Pfizer, a renowned New York drugmaker, has recently achieved expanded approval from the U.S. Food and Drug Administration (FDA) for its powerful combination of Braftovi and Mektovi drugs. This approval is specifically granted for the treatment of patients with metastatic non-small cell lung cancer who possess a BRAF V600E mutation.
With this significant milestone, Pfizer now offers a personalized treatment option for adults who are battling BRAF V600E-mutant metastatic non-small cell lung cancer. Considering that lung cancer remains the leading cause of cancer-related deaths worldwide, it is crucial to develop effective therapies. Non-small cell lung cancer accounts for more than 80% of all lung cancer cases, with approximately 2% of these cases being attributed to a BRAF V600E mutation, according to Pfizer.
The Braftovi/Mektovi combination has previously obtained FDA approval for patients dealing with unresectable or metastatic melanoma featuring a BRAF V600E or V600K mutation. Moreover, Braftovi is additionally approved in combination with cetuximab for adults who have metastatic colorectal cancer carrying a BRAF V600E mutation after undergoing prior therapy.
Pfizer’s acquisition of Array BioPharma in 2019, at the cost of $11.4 billion, led to the addition of Braftovi and Mektovi to its impressive portfolio.
For more information, please visit: www.pfizer.com